Phosphatidylserine (PS) is a phospholipid, one of the fat molecules that make up cell membranes. It is especially concentrated in nerve-cell membranes in the brain. As a dietary supplement it is sold mainly for memory in older adults, and in sports nutrition for its reported effect on the cortisol response to hard exercise.

The most important fact about PS is that the source changed. Most of the positive memory trials from the 1980s and early 1990s used PS extracted from cow brain (bovine cortex). Concern about mad cow disease moved the market to PS made from soy and, later, sunflower lecithin. That plant-derived PS has a different fatty-acid makeup, and the FDA has said results from one cannot simply be applied to the other. The FDA allows only a heavily qualified health claim, which must state that there is “little scientific evidence supporting this claim.”

This page summarizes what the clinical trials and FDA’s health-claim review report. It is for education only and is not medical advice.

Property	Detail
Class	Membrane phospholipid (glycerophospholipid); sold as a dietary supplement
Sources	Bovine brain cortex (BC-PS, used in older trials); soy or sunflower lecithin converted with serine (S-PS); marine-derived PS carrying DHA (PS-DHA)
Route	Oral; some early research used IV infusion
Doses studied	100–300 mg/day in memory trials; 600–800 mg/day in most exercise and cortisol studies
Half-life	Not established in humans; its pharmacokinetics “have not been fully elucidated”
Mechanism	Main negatively charged phospholipid of the inner layer of nerve-cell membranes; required for several signaling enzymes
US status	Dietary supplement, not an approved drug; FDA qualified health claims for dementia and cognitive dysfunction (2003, re-affirmed 2004)
WADA status	Not named on the WADA 2026 Prohibited List

What it is

Every PS molecule has the same basic layout: a glycerol-phosphate backbone, the amino acid serine as its “head group,” and two fatty-acid chains (FDA, May 2003). The body makes its own PS from two other membrane phospholipids, phosphatidylcholine and phosphatidylethanolamine, by swapping their head group for serine. Two enzymes in the endoplasmic reticulum, PS synthase 1 and 2, do this (Kim et al., Prog Lipid Res 2014).

In the brain, PS sits mostly in the inner layer of the cell membrane. There it helps switch on signaling proteins tied to nerve-cell survival (Akt, Raf-1 and protein kinase C) and modulates neurotransmitter release. Brain PS is rich in docosahexaenoic acid (DHA), an omega-3 fatty acid. The same NIH review notes that some memory improvement has been seen with PS supplements in cognitively impaired people, “but the mechanism is unclear” (Kim et al., 2014).

Bovine-cortex vs soy and sunflower PS

The fatty-acid chains are what differ between sources, and that is why the source matters when reading the trials.

Feature	Bovine-cortex PS (BC-PS)	Soy-derived PS (S-PS)
How it is made	Extracted and separated from brain tissue	Soy lecithin treated with serine and an enzyme to convert its phospholipids to PS
Main fatty acids	Mainly saturated and monounsaturated, plus long-chain omega-3 (about 8% DHA) and 2% arachidonic acid	Mainly polyunsaturated: about 47% linoleic acid (omega-6) and 7% alpha-linolenic acid (omega-3)
DHA-containing species	About 10%	None detected
Non-PS material in the ingredient	Up to 8%	15–80% for one manufacturer’s product
Trials that used it	Most positive memory trials (1986–1993); Monteleone cortisol studies	Most trials since 2000, including the later exercise studies

Sources: FDA, May 2003; Chen & Li, Chem Phys Lipids 2008.

The FDA concluded that, because of these differences, BC-PS and S-PS “may not be the same substance.” It said there is “considerable uncertainty” in applying results from bovine-PS studies to soy-PS products, and vice versa (FDA, November 2004).

The switch away from bovine PS was driven by safety. Bovine spongiform encephalopathy (BSE, “mad cow disease”) is caused by prions, and brain tissue is a high-risk material. A 2006 review describes soy PS as the preferred supplement “due to the possibility of transferring infection” from prion-contaminated brain (Kingsley, Sports Med 2006).

Sunflower-derived PS (sold, for example, as Sharp-PS Green) is a newer plant source. The only controlled trial of it we found was a pediatric study run partly by employees of the ingredient’s maker (see below). Products marketed as PS-DHA attach marine omega-3 fatty acids to the PS backbone, which is closer to the brain-derived profile (Vakhapova et al., BMC Neurol 2011).

How it works in the body

Human pharmacokinetic data for oral PS are thin. A review of PS in exercise notes that its pharmacokinetics “have not been fully elucidated.” It suggests that oral supplements probably cause small but measurable increases in membrane PS (Kingsley, 2006). No human elimination half-life has been published in the sources we reviewed.

The proposed mechanism for the cortisol findings is that PS dampens activation of the hypothalamic-pituitary-adrenal (HPA) axis, the hormone chain from brain to adrenal glands that drives cortisol release. The early studies measured lower ACTH (the pituitary hormone that signals the adrenals) along with lower cortisol (Monteleone et al., Eur J Clin Pharmacol 1992). This is a working hypothesis, not an established mechanism.

Regulatory status: the FDA qualified health claims

PS is not an FDA-approved drug. In 2002 a petition on behalf of Dr. Kyl Smith asked FDA to authorize two health claims for PS supplements. FDA found that the evidence did not meet the “significant scientific agreement” standard needed for an authorized health claim. Instead, in letters dated February 24 and May 13, 2003, it agreed to use “enforcement discretion” for two qualified claims (FDA, February 2003; FDA, May 2003). The exact permitted wording is:

Dementia: “Consumption of phosphatidylserine may reduce the risk of dementia in the elderly. Very limited and preliminary scientific research suggests that phosphatidylserine may reduce the risk of dementia in the elderly. FDA concludes that there is little scientific evidence supporting this claim.”
Cognitive dysfunction: “Consumption of phosphatidylserine may reduce the risk of cognitive dysfunction in the elderly. Very limited and preliminary scientific research suggests that phosphatidylserine may reduce the risk of cognitive dysfunction in the elderly. FDA concludes that there is little scientific evidence supporting this claim.”

FDA attached conditions to these claims (FDA, May 2003):

the disclaimer must sit directly beneath the claim, with nothing in between, in the same size, typeface and contrast;
if soy PS is used, it must be “of very high purity”;
bovine PS, if used, must not come from cattle born, raised or slaughtered in any country where BSE exists;
the claim does not have to state a daily intake.

The claims are about reducing risk in older adults. They are not claims that PS treats dementia. In its later review, FDA judged the trials in people who already had dementia not relevant to risk reduction, and five open-label trials not scientifically credible (FDA, November 2004).

In November 2004, FDA re-reviewed the evidence and kept the same wording. It identified four relevant controlled trials in people at risk but without dementia. Three used bovine PS and were positive; the one soy-PS trial (Jorissen et al., 2001) found no benefit (FDA, November 2004). FDA listed flaws in these trials, including:

multiple comparisons without statistical correction;
missing data on completers;
unvalidated outcome measures;
subgroups that were defined after the study.

FDA lists both letters on its qualified health claims page.

What the research shows

Memory and cognition in older adults

The trials split cleanly by source. Most bovine-PS trials reported some benefit, mostly on a minority of the outcomes measured. The soy-PS trials were mostly negative or positive only in subgroups.

Trial	PS source and dose	Population (n)	Duration	Main result
Crook et al., Neurology 1991	BC-PS 100 mg three times daily	Age-associated memory impairment (149)	12 weeks	Better than placebo on some learning and memory tests (6 of 20 outcome measures per FDA’s count); gains concentrated in the lower-performing subgroup
Crook et al., Psychopharmacol Bull 1992	BC-PS 100 mg three times daily	Probable Alzheimer’s disease (51)	12 weeks	Improved on several cognitive measures; differences mainly in milder cases
Engel et al., Eur Neuropsychopharmacol 1992	BC-PS 300 mg/day, crossover	Mild Alzheimer-type dementia (33)	8 weeks per phase	More patients improved on clinician global rating; no significant change on dementia rating scale or psychometric tests
Cenacchi et al., Aging 1993	BC-PS 300 mg/day	Ages 65–93 with moderate to severe cognitive decline (494; 69 dropped out)	6 months	Significant improvement vs placebo on behavioral and memory scales
Jorissen et al., Nutr Neurosci 2001	S-PS 300 or 600 mg/day	Age-associated memory impairment, over 57 (120)	12 weeks	No difference from placebo on any outcome
Kato-Kataoka et al., J Clin Biochem Nutr 2010	S-PS 100 or 300 mg/day	Memory complaints, ages 50–69 (78)	6 months	All groups, including placebo, improved similarly; memory gains vs baseline only in a low-scoring subgroup
Vakhapova et al., Dement Geriatr Cogn Disord 2010	PS-DHA, 300 mg PS/day	Non-demented, memory complaints (157)	15 weeks	Verbal immediate recall better than placebo; other gains only in post hoc subgroups

Several features limit how much weight the older positive trials can carry:

They used a product no longer sold, often from one company. The Engel trial used bovine PS from Fidia, and the first author of the largest trial was at Fidia Research Laboratories (Cenacchi et al., 1993; Engel et al., 1992).
Many outcomes, few hits. FDA found that in five of ten intervention trials, only “a very small number of outcome measures” out of many reached significance (FDA, May 2003).
Subgroup-driven results. Benefits were often reported only in people who scored lowest at baseline, defined after randomization (Crook et al., 1991; Kato-Kataoka et al., 2010).

A 2003 review of “brain-specific” nutrients reached a similar conclusion. In older adults with moderate cognitive impairment, PS “produced consistently modest increases in recall of word lists,” with less consistent effects on other memory tests (McDaniel et al., Nutrition 2003).

Meta-analyses and systematic reviews

We did not find a meta-analysis that pools PS trials alone for age-related memory decline. The pooled evidence that exists is indirect or comes from small trial sets:

Review	Scope	PS finding
Li et al., Nutr Neurosci 2026	Network meta-analysis of supplements in Alzheimer’s disease or mild cognitive impairment; 29 RCTs, n = 2,000	PS 100 mg was among the supplements that outperformed placebo on the MMSE (mean difference 1.14 points in favor of PS, 95% CI 0.41–1.86). No supplement improved the ADAS-Cog, the standard Alzheimer’s drug-trial cognition scale
Bruton et al., J Altern Complement Med 2021	PS for pediatric ADHD; 3 RCTs in the meta-analysis, n = 216	200–300 mg/day improved inattention (effect size 0.36, 95% CI 0.07–0.64); overall ADHD symptoms (0.76, 95% CI −0.07 to 1.60) and hyperactivity (0.24, 95% CI −0.04 to 0.53) were not significant; evidence quality rated low
Kucuksahin et al., Hum Psychopharmacol 2026	Citicoline or PS in mental disorders; 11 controlled studies	Findings “heterogeneous and inconsistent”; evidence does not support either as cognitive enhancers in these conditions

The MMSE (Mini-Mental State Examination) is a 30-point screening test for cognitive impairment. A 1-point gain is small, and the absence of any effect on the ADAS-Cog in the same analysis argues for caution.

Children

Two pediatric trials used plant-derived PS:

ADHD: In a double-blind trial in 36 children aged 4–14, ADHD symptom scores and short-term auditory memory improved on soy PS 200 mg/day for 2 months, with no significant change on placebo (Hirayama et al., J Hum Nutr Diet 2014).
Healthy children: In children aged 8–12, sunflower PS 100 mg/day for 12 weeks showed no difference from placebo on primary or secondary outcomes. A pre-defined low-performing subgroup improved on one visuospatial memory task. Four authors were employees of the company selling that ingredient (Friling et al., Nutr J 2025).

Exercise, cortisol and stress

The cortisol story began with bovine PS in very small studies, and the soy-PS replications are mixed.

Study	Design and n	PS source and dose	Main result
Monteleone et al., Neuroendocrinology 1990	Double-blind, 3 cycling sessions; 8 healthy men	BC-PS 50 or 75 mg IV before exercise	Both doses blunted the ACTH and cortisol rise
Monteleone et al., Eur J Clin Pharmacol 1992	Placebo-controlled; 9 healthy men	BC-PS 800 mg/day oral, 10 days	Blunted ACTH (p = 0.003) and cortisol (p = 0.03) responses; no effect on growth hormone or prolactin
Kingsley et al., MSSE 2005	Double-blind, PS vs placebo groups; 16 male soccer players	S-PS 750 mg/day, 10 days	No effect on cortisol, soreness, muscle-damage or oxidative-stress markers; run time to exhaustion +4.2% vs −3.7% (p = 0.084, not significant)
Kingsley et al., MSSE 2006 (cycling)	Double-blind, PS vs placebo groups; 14 active men	S-PS 750 mg/day, 10 days	Time to exhaustion at 85% VO2max rose from 7:51 to 9:51 min:s on PS (placebo unchanged); no effect on cortisol
Kingsley et al., MSSE 2006 (downhill running)	Double-blind crossover; 8 men	S-PS 750 mg/day, 7 days before and 2 days after	No reduction in soreness, creatine kinase, IL-6 or oxidative-stress markers
Starks et al., JISSN 2008	Double-blind, placebo-controlled crossover; 10 healthy men	S-PS 600 mg/day, 10 days	Peak cortisol 39% lower and cortisol AUC 35% lower vs placebo; testosterone-to-cortisol ratio AUC 184% higher; no effect on lactate or growth hormone
Hellhammer et al., Lipids Health Dis 2014	Double-blind, 3 arms; 75 men, psychosocial stress test	Soy PS plus phosphatidic acid, 400 + 400 mg or 200 + 200 mg/day, 42 days	Higher dose normalized ACTH and cortisol responses only in highly stressed men; lower dose had no effect

AUC (area under the curve) is the total hormone exposure over the sampling period. Details of the Starks trial matter for interpreting it:

Short exercise bout. The exercise was 15 minutes of moderate-to-hard cycling, and the men had a low average aerobic fitness (VO2max 29 mL/kg/min).
Industry funding. It was funded by Increnovo LLC, the employer of two co-authors, and Chemi Nutra paid for publication (Starks et al., full text).
Replication. Kingsley’s group, using a higher soy dose (750 mg/day), found no cortisol effect in either of two exercise trials. The Starks authors themselves describe the earlier soy-PS findings as “equivocal” and possibly dose-dependent.

Other sports studies tested PS for outcomes other than cortisol:

Golf: In a double-blind trial in 20 young golfers, good tee shots out of 20 rose from 8.3 to 10.1 on 200 mg/day for 42 days (in a nutrition bar), with no change on placebo; perceived stress showed only a trend (p = 0.07) (Jäger et al., JISSN 2007).
Resistance exercise: A supplement with 400 mg PS plus 100 mg caffeine daily for 2 weeks reduced post-exercise fatigue and mood disturbance but did not change cognition or reaction time (Wells et al., Nutr Res 2013). Because caffeine was included, the effect cannot be credited to PS alone.

No controlled trial in our sources measured muscle mass, strength gains or body composition with PS. Claims that PS is “anabolic” or helps preserve muscle by lowering cortisol are extrapolations from short-term hormone measurements, not demonstrated outcomes.

Side effects and risks

Tolerability in trials

Controlled trials have reported PS as well tolerated, though most were small and lasted 3–6 months or less:

Bovine PS: In the 494-patient Cenacchi trial (300 mg/day for 6 months), clinical evaluation and laboratory tests showed BC-PS was well tolerated (Cenacchi et al., 1993).
Soy PS: In 120 older adults given 300 or 600 mg/day for 12 weeks, there were no differences from placebo in blood chemistry, blood counts, blood pressure, heart rate or adverse events after statistical correction (Jorissen et al., Nutr Neurosci 2002). A 6-month Japanese trial at 100–300 mg/day found no changes in blood markers or vital signs (Kato-Kataoka et al., 2010).
PS-DHA: At 300 mg PS/day for 15 weeks there were no safety differences vs placebo. After a further 15-week open-label phase at 100 mg/day, people who had taken PS-DHA for 30 weeks showed a reduction in resting diastolic blood pressure and slight weight gain (Vakhapova et al., 2011).
Children: No adverse effects were reported with soy PS 200 mg/day in children with ADHD (Hirayama et al., 2014).

Prion risk from bovine PS

FDA’s safety conclusion for the health claim depended on the source. It found PS safe and lawful as a supplement “provided that bovine-derived sources, if used, are not derived from bovine tissues from cattle born, raised, or slaughtered in any country where BSE exists” (FDA, May 2003). The concern is variant Creutzfeldt-Jakob disease, the human prion disease linked to eating BSE-contaminated beef products.

Purity and product variation

FDA noted that the non-PS content of soy-PS ingredients from one manufacturer ranged from 15% to 80%. These other phospholipids and free fatty acids may have their own biological effects. That is why the health claim for soy PS is conditioned on very high purity (FDA, May 2003). More broadly, FDA does not approve dietary supplements’ safety, effectiveness or labeling before they are sold (Hersant et al., CNS Drugs 2023).

Interactions and who lacks data

We found no formal drug-interaction studies of oral PS in the sources reviewed. Trials enrolled mainly older adults, healthy young men and children with ADHD. We found no data on pregnancy, breastfeeding or long-term use beyond about 6–7 months.

PS is often sold alongside choline-based supplements marketed for memory. Citicoline (CDP-choline) and Alpha-GPC supply choline rather than PS, and each has its own, separate evidence base.

Key takeaways

The source changes the evidence. Most positive memory trials used bovine-brain PS, which is no longer used because of prion risk. FDA says soy and bovine PS “may not be the same substance.”
The FDA claim is a disclaimer more than an endorsement. Labels may say PS “may reduce the risk” of dementia or cognitive dysfunction in the elderly only if they add that “FDA concludes that there is little scientific evidence supporting this claim.”
Plant-derived PS trials are weak or negative. The largest soy-PS trial in memory impairment found no benefit at 300 or 600 mg/day; other positive findings come from subgroups or small, often industry-linked studies.
The cortisol effect is small-sample and inconsistent. Starks 2008 (n = 10, 600 mg/day) reported 35–39% lower cortisol after a short cycling bout, but two Kingsley trials at 750 mg/day found no cortisol effect. No trial shows muscle or strength benefits.
Well tolerated in trials up to about 6 months. Doses of 100–600 mg/day produced no meaningful safety signals in controlled safety assessments, but long-term and pregnancy data are lacking.

Sources

Kim HY, Huang BX, Spector AA. Phosphatidylserine in the brain: metabolism and function. Prog Lipid Res. 2014;56:1–18. PubMed.
Kingsley M. Effects of phosphatidylserine supplementation on exercising humans. Sports Med. 2006;36(8):657–669. PubMed.
Food and Drug Administration. Letter regarding dietary supplement health claim for phosphatidylserine and cognitive dysfunction and dementia (Docket 02P-0413). February 24, 2003. FDA archive.
Food and Drug Administration. Phosphatidylserine and cognitive dysfunction and dementia: letter of enforcement discretion to J.W. Emord and A.G. Ferrenz (Docket 02P-0413). May 13, 2003. FDA archive.
Food and Drug Administration. Letter updating the phosphatidylserine and cognitive function and dementia qualified health claim. November 24, 2004. FDA archive.
Food and Drug Administration. Qualified health claims: letters of enforcement discretion. FDA.
Chen S, Li KW. Comparison of molecular species of various transphosphatidylated phosphatidylserine (PS) with bovine cortex PS by mass spectrometry. Chem Phys Lipids. 2008;152(1):46–56. PubMed.
Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology. 1991;41(5):644–649. PubMed.
Crook T, Petrie W, Wells C, et al. Effects of phosphatidylserine in Alzheimer’s disease. Psychopharmacol Bull. 1992;28(1):61–66. PubMed.
Engel RR, Satzger W, Günther W, et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol. 1992;2(2):149–155. PubMed.
Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano). 1993;5(2):123–133. PubMed.
Jorissen BL, Brouns F, Van Boxtel MP, et al. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. Nutr Neurosci. 2001;4(2):121–134. PubMed.
Jorissen BL, Brouns F, Van Boxtel MP, et al. Safety of soy-derived phosphatidylserine in elderly people. Nutr Neurosci. 2002;5(5):337–343. PubMed.
Kato-Kataoka A, Sakai M, Ebina R, et al. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. J Clin Biochem Nutr. 2010;47(3):246–255. PubMed.
Vakhapova V, Cohen T, Richter Y, et al. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord. 2010;29(5):467–474. PubMed.
Vakhapova V, Richter Y, Cohen T, et al. Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension. BMC Neurol. 2011;11:79. PubMed.
McDaniel MA, Maier SF, Einstein GO. “Brain-specific” nutrients: a memory cure? Nutrition. 2003;19(11-12):957–975. PubMed.
Li Y, Leng Q, Wang Y. The impact of supplements on cognitive function for Alzheimer’s disease or mild cognitive impairment: a systematic review and network meta-analysis. Nutr Neurosci. 2026:1–19. PubMed.
Bruton A, Nauman J, Hanes D, et al. Phosphatidylserine for the treatment of pediatric attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. J Altern Complement Med. 2021;27(4):312–322. PubMed.
Kucuksahin NG, Kaya TT, Halac E, et al. The impact of citicoline/phosphatidylserine supplementation on cognitive performance and executive functions in mental disorders: a systematic review of controlled trials. Hum Psychopharmacol. 2026;41(5):e70058. PubMed.
Hirayama S, Terasawa K, Rabeler R, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet. 2014;27(Suppl 2):284–291. PubMed.
Friling M, Jackson PA, Kennedy D, et al. The cognitive effects of supplementation with sunflower phosphatidyl serine in healthy children aged 8 to 12 years: a randomized controlled trial. Nutr J. 2025;25(1):3. PubMed.
Monteleone P, Beinat L, Tanzillo C, et al. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology. 1990;52(3):243–248. PubMed.
Monteleone P, Maj M, Beinat L, et al. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol. 1992;42(4):385–388. PubMed.
Kingsley MI, Wadsworth D, Kilduff LP, et al. Effects of phosphatidylserine on oxidative stress following intermittent running. Med Sci Sports Exerc. 2005;37(8):1300–1306. PubMed.
Kingsley MI, Miller M, Kilduff LP, et al. Effects of phosphatidylserine on exercise capacity during cycling in active males. Med Sci Sports Exerc. 2006;38(1):64–71. PubMed.
Kingsley MI, Kilduff LP, McEneny J, et al. Phosphatidylserine supplementation and recovery following downhill running. Med Sci Sports Exerc. 2006;38(9):1617–1625. PubMed.
Starks MA, Starks SL, Kingsley M, et al. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr. 2008;5:11. PubMed; PMC.
Hellhammer J, Vogt D, Franz N, et al. A soy-based phosphatidylserine/ phosphatidic acid complex (PAS) normalizes the stress reactivity of hypothalamus-pituitary-adrenal-axis in chronically stressed male subjects: a randomized, placebo-controlled study. Lipids Health Dis. 2014;13:121. PubMed.
Jäger R, Purpura M, Geiss KR, et al. The effect of phosphatidylserine on golf performance. J Int Soc Sports Nutr. 2007;4:23. PubMed.
Wells AJ, Hoffman JR, Gonzalez AM, et al. Phosphatidylserine and caffeine attenuate postexercise mood disturbance and perception of fatigue in humans. Nutr Res. 2013;33(6):464–472. PubMed.
Hersant H, He S, Maliha P, et al. Over the counter supplements for memory: a review of available evidence. CNS Drugs. 2023;37(9):797–817. PubMed.
World Anti-Doping Agency. The 2026 Prohibited List. WADA 2026 Prohibited List.

Phosphatidylserine